UCB and Ariceum Therapeutics sign a Strategic Research Collaboration
Friday, May 12, 2023
UCB and Ariceum Therapeutics announced an exclusive strategic research collaboration agreement to identify and develop novel systemic targeted radiopharmaceuticals for the treatment of immune-related diseases and solid tumours.
Under the terms of the research collaboration, UCB and Ariceum will utilize each other’s proprietary technology platforms to enable the discovery of peptide-radioisotope conjugates as potential therapeutics for immune-related diseases and cancer. Ariceum will also gain access to UCB’s expertise to discover novel synthetic macrocyclic peptides using its mRNA-display technology platform, ExtremeDiversity™.
UCB will benefit from Ariceum’s expertise in the field of radiochemistry and labelling technology to enhance its ability to explore how this technology will lead to the discovery of highly differentiated products for immune-related diseases.
The collaboration with Ariceum further enhances strategic drug discovery capabilities and provides UCB with the opportunity to learn and explore the potential of this modality to continuously innovate.
Through this partnership, Ariceum will have access to a unique library that will be used to screen against targets of interest for oncology for which current targeted approaches have failed while working with UCB on enabling targeted systemic radiotherapy approaches in other areas of severe diseases.
